Member Info for OXBIGTIME

Babbler what is seller ms ? Loss of buys going on, mainly small? Puzzled why such great news has not got the SP going to dizzying heights. Market was closed before the news yesterday. I was waiting for the ten o'clock news to headline gene therapy advancement and British firms involvement. Lol. Been patient for a long time.

Something's afoot. Market reaction not positive enough. You'd expect people to pile in. Too easy for me to buy at 10.2. Why was the SP 9.35 first thing? If the SP does not go to 11 or 12 I'd think OXB's deal with Novartis is not good enough. Any other ideas?

The actual document Novartis present today in the US is online. Here's a snippet: Tisagenlecleucel demonstrates compelling and consistent clinical efficacy with high response rates,and deep and durable remissions,in the majority of patients without additional therapies, across three pediatric and young adult r/r B-cell ALL studies (pivotal Study B2202 and supportive Studies B2101J andB2205J) Tisagenlecleucel represents a new treatment paradigm and a major improvement in the treatment of these patients with high unmet medical need Read it all at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566168.pdf

Don't think there will be a decision or announcement tomorrow, maybe some press? Hardman report says tomorrow is a meeting and any formal approval will be in Sept. anyone else any thoughts or knowledge? I don't think the Novartis deal just done which was for 100m over 3 years is dependent on the approval. I'm guessing Novartis and OXB were both hedging their bets. Novartis being shrewd OXB for survival. Anyone agree?

Exactly. SP has gone up on the back of all the media. Reads like Novartis deal is in place if not already delivered come what may. Refinancing. Hopefully an end to more share dilution. I hear on the grapevine OXB staff are very excited at the company's prospects at the moment. More products in the pipeline. After all these years seems like OXB has cracked gene manipulation for treating both terminal conditions and improving health. All the best.

just realised it's only a meeting next week, final decision will be Sept. according to Hardman Research: Deal timing The timing of this deal is significant. The FDA accepted Novartis’s Biologics License Application (BLA) filling of CTL019 for relapsed/refractory B cell acute lymphoblastic leukaemia (r/r B-ALL) in March 2017. It was awarded a ‘Priority Review’, signifying particular treatment improvement compared to standard therapy, and a shortened FDA processing timeline (within six months). As such, following the FDA Oncologic Drugs Advisory Committee (ODAC) meeting scheduled for 12th July at which CTL019 will be independently reviewed, a final decision is expected by September 2017. It is likely that CTL019 will become the first FDA approved CAR-T therapy.

Nothing to worry about. He did not work for OXB. All the banter just got him worked up. For what it's worth I've held OXB for around a decade and have bought and sold. As with all my dealing there is "if only". Well at the moment I hold a sizeable share of my SIPP in OXB so am hoping for good news next week. I'd anticipate a doubling in price, around 18p-20p then profit taking and a drop to 14-16. Long term anybody's guess, I like OXB and am in for the long term. Maybe dividends one day, more cures, more success. We talked on the phone for quite a while. Lovely bloke just a bit miss guided. GLA Strong buy and as always a bit of a gamble!

Hi. I'd like to make contact and have a chat sometime. My number 07802791617. Hope to hear from you.

Thanks for the info on PF-06263507. There is food for thought. OXB's site has not been updated and the Edison report that was messaged on Monday still referred to the on going clinical trial. The U.S. Clinical trials.gov site states the trials were discontinued by Pfizer (The study was terminated on June 23, 2015 due to the company's change in prioritization for the portfolio and is not due to any safety concerns.) I don't know why the dissemination of info takes so long. If have expected OXB to put out some sort of statement and update their site. Not sure the share price has or will be affected, the Novartis deal is the main driver not Pfizer.

Great post wblack. I scrolled down the stories until I found the one about Jake. CTL019 - OXB's deal with Novartis includes production and they will get undisclosed royalties. I don't think the wait for some great returns is going to be too long now. Will be interesting to see what good financial news there is in the OXB August report. amazing the research investors like you are reporting, well done!

Thanks wblack. That's reassuring info. Be good of OXB to disclose the royalties revenues some time in the future. Guess that's sensitive commercial info. The video from Novartis was exciting, just as much for me as the scientists. So good news that the video was published on the 30th June 2015.

Hi nipper. I need a bit more convincing that that Novartis collaboration with Penn University on CAR-T and in particular CTL019 benefits OXB. Can you help?

Thanks for the info on the Trovax story. Sad for the patient whose cancer has returned. I'd think there will always be failures as well as success stories. Hopefully this case will not be a sign that Trovax does not work. I'm hoping the figures overall will be positive. Trovax I think has been developed over 10yrs. Results from 10 previous clinical trials in colorectal, renal and prostate cancer have shown that TroVax® is safe and well tolerated in over 500 patients; can be administered in combination with various other treatments and show clear indication of efficacy. Approximately 90 per cent of patients treated with TroVax® mounted an anti-cancer immune response to the 5T4 antigen. - See more at: http://www.oxfordbiomedica.co.uk/trovax-r/#. The reference in the news article to Dec 2015 I think is a typo and should have been 2014.

On the company website under investors. Apologies Tim Watts is Chief Financial Officer not CEO. Looks positive. Going forward the bonus scheme announced 8th May will make senior management very rich when the share price rises and they choose to cash in. MMs look to be making a killing with the price drop. I'd like to find out who bought the 4.6m shares, any ideas?

Oxford, UK - 20 May 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 19 May 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows: Interest after purchase Director / PDMR Title Price per share (p) Number of Ordinary Shares acquired Number of Ordinary Shares % of total issued share capital Tim Watts Chief Financial Officer 10.3p 194,174 5,802,003 0.23%

All this activity in the last two days has been unsettling for me. Still I thought I'd buy in at 16.27hrs when the SP was 9.5. Order (£2,500) could not be fulfilled as the market makers were at that time not offering a price on the system (according to TD Investing). Bugger me when I see someone may have bought 4.6m shares at price of 10.45. Though I do not trust reporting. Could well have been a sell at the beginning of the day and not reported until after trading, is this possible? Lets see what happens next....